Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study

BMC Genomics

Volumn 13, Issue 1, 2012, Pages

  Budczies, Jan ^a   Denkert, Carsten ^a   Müller, Berit M ^a   Brockmöller, Scarlet F ^a   Klauschen, Frederick ^a   Györffy, Balazs ^a,b   Dietel, Manfred ^a   Richter Ehrenstein, Christiane ^a   Marten, Ulrike ^c   Salek, Reza M ^d   Griffin, Julian L ^d   Hilvo, Mika ^e   Orešič, Matej ^e   Wohlgemuth, Gert ^f   Fiehn, Oliver ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c German Red Cross Hospital   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Cancer detection; Gas chromatography; Mass spectrometry; Metabolomics

Indexed keywords

2,5 DIHYDROXYPYRAZINE; ADENOSINE PHOSPHATE; BENZOIC ACID; CREATININE; CYTIDINE PHOSPHATE; DECANOIC ACID DERIVATIVE; GLUTAMIC ACID; GLYCEROPHOSPHATE; GLYCOLIC ACID; HEPTADECANOIC ACID; HEXADECANOL; HYDROXYLAMINE; HYPOXANTHINE; LIGNOCERIC ACID; MALIC ACID; MALONIC ACID; N ACETYLASPARTIC ACID; OXOPROLINE; PENTADECANOIC ACID; PHOSPHOETHANOLAMINE; PROLINE DERIVATIVE; PYRAZINE DERIVATIVE; TAURINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENERGY METABOLISM; GAS CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLOMICS; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY;

AMINO ACIDS; BREAST; BREAST NEOPLASMS; CLUSTER ANALYSIS; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCEROPHOSPHOLIPIDS; HUMANS; METABOLOMICS; NEOPLASM INVASIVENESS; NUCLEOTIDES; PRINCIPAL COMPONENT ANALYSIS;

EID: 84865602043     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-13-334     Document Type: Article

References (37)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
2. Warburg O. On the origin of cancer cells. Science (80- ) 1956, 123:309-314.
3. Tennant DA, Durán RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009, 30:1269-1280. 10.1093/carcin/bgp070, 19321800.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (80- ) 2009, 324:1029-1033.
5. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004, 5:341-351. 10.1016/S1535-6108(04)00080-7, 15093541.
6. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004, 4:551-561. 10.1038/nrc1390, 15229480.
7. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980. 10.1158/0008-5472.CAN-05-4673, 16778164.
8. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276. 10.1158/0008-5472.CAN-03-3829, 15205341.
9. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777. 10.1038/nrc2222, 17882277.
10. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482. 10.1016/j.ccr.2008.05.005, 18538731.
11. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010, 70:859-862. 10.1158/0008-5472.CAN-09-3556, 2818441, 20086171.
12. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277. 10.1038/nrc2817, 20300106.
13. Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyötyläinen T, Kallioniemi O, Iljin K, Oresic M. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011, 71:3236-3245. 10.1158/0008-5472.CAN-10-3894, 21415164.
14. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, Niesporek S, Noske A, Buckendahl A, Dietel M, Fiehn O. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008, 7:72. 10.1186/1476-4598-7-72, 2569965, 18799019.
15. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Könsgen D, Dietel M, Fiehn O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006, 66:10795-10804. 10.1158/0008-5472.CAN-06-0755, 17108116.
16. Kind T, Wohlgemuth G, Lee DY, Lu Y, Palazoglu M, Shahbaz S, Fiehn O. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem 2009, 81:10038-10048. 10.1021/ac9019522, 2805091, 19928838.
17. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet 2005, 365:1727-1741. 10.1016/S0140-6736(05)66546-4, 15894099.
18. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
19. Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010, 12(Suppl 2):S3. 10.1186/bcr2574, 3005723, 21172087.
20. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res 2010, 12(Suppl 2):S1. 10.1186/bcr2572, 3005721, 21172071.
21. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365:488-492. 10.1016/S0140-6736(05)17866-0, 15705458.
22. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899. 10.1038/nrc1478, 15516961.
23. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007, 104:19345-19350. 10.1073/pnas.0709747104, 2148292, 18032601.
24. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 1990, 46:243-271. 10.1016/0163-7258(90)90094-I, 2108451.
25. Wang J, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio ALB, Dias SMG, Dang CV, Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18:207-219. 10.1016/j.ccr.2010.08.009, 3078749, 20832749.
26. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004, 64:8534-8540. 10.1158/0008-5472.CAN-04-1945, 15574759.
27. Wu G, Vance DE. Choline kinase and its function. Biochem Cell Biol 2010, 88:559-564. 10.1139/O09-160, 20651826.
28. Malcolm A, Wright S, Syms RRA, Dash N, Schwab M, Finlay A. Miniature mass spectrometer systems based on a microengineered quadrupole filter. Anal Chem 2010, 82:1751-1758. 10.1021/ac902349k, 20108919.
29. Ouyang Z, Cooks RG. Miniature mass spectrometers. Annu Rev Anal Chem (Palo Alto Calif) 2009, 2:187-214.
30. Contreras JA, Murray JA, Tolley SE, Oliphant JL, Tolley HD, Lammert SA, Lee ED, Later DW, Lee ML. Hand-portable gas chromatograph-toroidal ion trap mass spectrometer (GC-TMS) for detection of hazardous compounds. J Am Soc Mass Spectrom 2008, 19:1425-1434. 10.1016/j.jasms.2008.06.022, 18672381.
31. Advanced interfaced micro-systems research for analysis of real-world clinical, food, environmental and waste samples (ARROWS) European FP7 Collaborative Project, , http://www.arrows-online.eu.
32. Sansone S, Fan T, Goodacre R, Griffin JL, Hardy NW, Kaddurah-Daouk R, Kristal BS, Lindon J, Mendes P, Morrison N, Nikolau B, Robertson D, Sumner LW, Taylor C, van der Werf M, van Ommen B, Fiehn O. The metabolomics standards initiative. Nat Biotechnol 2007, 25:846-848.
33. R: a language and environment for statistical computing , , http://www.r-project.org.
34. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012, 40:D109-D114. 10.1093/nar/gkr988, 3245020, 22080510.
35. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13:2498-2504. 10.1101/gr.1239303, 403769, 14597658.
36. Gao J, Tarcea VG, Karnovsky A, Mirel BR, Weymouth TE, Beecher CW, Cavalcoli JD, Athey BD, Omenn GS, Burant CF, Jagadish HV. Metscape: a Cytoscape plug-in for visualizing and interpreting metabolomic data in the context of human metabolic networks. Bioinformatics 2010, 26:971-973. 10.1093/bioinformatics/btq048, 2844990, 20139469.
37. Budczies J, Kosztyla D. Cancerclass: an R package for development and validation of diagnostic tests from high-dimensional molecular data , , Available from the Bioconductor repository. http://www.bioconductor.org.